Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
Summary
The chemokine CXCL8 plays a key role in the recruitment and activation of polymorphonuclear neutrophils in post-ischemia reperfusion injury after solid organ transplantation. Reparixin is a novel, specific inhibitor of CXCL8. This study is configured to explore the safety and efficacy of reparixin in preventing the delayed graft function (DGF) after kidney transplantation.
Timeline
- Start
- 2005-10
- Primary completion
- 2008-05
- Completion
- 2008-06
Outcome
Missed primary endpoint
registry analysis (superiority test); Reparixin Continuous Infusion vs Placebo Continuous/Intermittent Infusion; p = 0.9076; Difference between means -0.275 (95% CI -5.00 to 4.45); Other NCT00248040 ↗
registry analysis (superiority test); Reparixin Intermittent Infusion vs Placebo Continuous/Intermittent Infusion; p = 0.3084; Difference between means 2.444 (95% CI -2.32 to 7.21); Other NCT00248040 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Reparixin | Small molecule | 2.244 mg/kg | Intravenous |
| Subject | Reparixin | Small molecule | 2.772 mg/kg | Intravenous |